300 related articles for article (PubMed ID: 9242555)
21. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
[TBL] [Abstract][Full Text] [Related]
22. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
[TBL] [Abstract][Full Text] [Related]
23. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
[TBL] [Abstract][Full Text] [Related]
24. [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients].
Polák J; Marková J; Schwarz J; Maaloufová J; Volková Z; Cermák J; Haskovec C
Cas Lek Cesk; 2006; 145(1):36-42. PubMed ID: 16468240
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
27. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
[TBL] [Abstract][Full Text] [Related]
29. Quantification of WT1 mRNA by competitive NASBA in AML patients.
Fukahori S
Kurume Med J; 2001; 48(2):129-34. PubMed ID: 11501493
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
31. Expression of Wilms tumor gene (WT1) in children with acute leukemia.
Im HJ; Kong G; Lee H
Pediatr Hematol Oncol; 1999; 16(2):109-18. PubMed ID: 10100271
[TBL] [Abstract][Full Text] [Related]
32. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
Ogawa H; Tamaki H; Ikegame K; Soma T; Kawakami M; Tsuboi A; Kim EH; Hosen N; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Oji Y; Oka Y; Sugiyama H
Blood; 2003 Mar; 101(5):1698-704. PubMed ID: 12406915
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia.
Garg M; Moore H; Tobal K; Liu Yin JA
Br J Haematol; 2003 Oct; 123(1):49-59. PubMed ID: 14510942
[TBL] [Abstract][Full Text] [Related]
34. [Expression of Wilms' tumor gene (WT1) in leukemias and its clinical implication].
Wu X; Wang Y; Pei X
Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):16-9. PubMed ID: 10921096
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
36. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Paschka P; Holland KB; Schwind S; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
Blood; 2010 Aug; 116(5):788-92. PubMed ID: 20442368
[TBL] [Abstract][Full Text] [Related]
37. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
[TBL] [Abstract][Full Text] [Related]
38. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.
King-Underwood L; Pritchard-Jones K
Blood; 1998 Apr; 91(8):2961-8. PubMed ID: 9531607
[TBL] [Abstract][Full Text] [Related]
39. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies.
Yokoyama A; Okabe-Kado J; Wakimoto N; Kobayashi H; Sakashita A; Maseki N; Nakamaki T; Hino Ki; Tomoyasu S; Tsuruoka N; Motoyoshi K; Nagata N; Honma Y
Blood; 1998 Mar; 91(6):1845-51. PubMed ID: 9490665
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
